Commissariat a L'energie Atomique Et Aux Energies Alternatives

Centre National De La Recherche Scientifique

Institut National De La Sante Et De La Recherche Medicale

Université´ D'aix-Marseille

Université Grenoble Alpes

Institut Curie

Université Paris Sud-Paris Xi

Caroline Barette

Emmanuelle Soleilhac

Catherine Pillet

Jean-Christophe Cintrat

Eric Marechal

Christian Rivalle

Claude Cochet

Yung-Sing Wong

Juliette Jouhet

Laurence Lafanechère

Fabrice Rebeille

Odile Filhol

Renaud Prudent

Coline Mei

Patrice Vanelle

Dimitris Petroutsos

Carmen Aguilar

Denis Falconet

Magda Mortier

Sofia Giacosa

Sophie Ple

Ina Attree

ChiHung Nguyen

Emilie Vassal

Vincent Remusat

Marie-Odile Fauvarque

Melissa Conte

Thierry Terme

Lina-Juana Dolch

The present invention concerns heterocyclic naphthoquinones derivatives for use in the treatment of Cushing disease and other cancers, in particular via the inhibition of Ubiquitin Specific Proteases (USP) 8 and/or 2.

Heterocyclic naphthoquinones derivatives for use in the treatment of cancers including Cushing disease

The invention relates to a method of identifying molecules which inhibit the virulence machinery ofto a device for identifying a molecule which inhibits the virulence machinery ofto novel compounds which inhibit the virulence machinery ofto compounds for use for preventing and/or treating a pathogenic infection caused byand also to pharmaceutical compositions for preventing and/or treating a pathogenic infection caused by

Pseudomonas aeruginosa inhibitor compounds

The invention relates to a method for accumulating triacylglycerols in microalgae by inhibiting the sterol metabolism, by incubating the microalgae with an inhibitor of sterol metabolism. The invention also relates to a method for producing fatty acids, biofuels, pharmaceutical or cosmetic compositions, and also food supplements, comprising a triacylglycerols accumulation step in microalgae according to the invention. Finally, the invention concerns the use of an inhibitor of sterol metabolism to accumulate triglycerides in microorganisms, and preferably microalgae.

Inhibitors of sterol metabolism for their use to accumulate triglycerides in microalgae, and methods thereof

The present invention pertains to a novel treatment of renal cell carcinoma and other a solid tumors which harbor a VHL inactivation, based on the combination of a first agent inhibiting a protein kinase CK2 (CK2) and a second agent inhibiting an Ataxia Telangiectasia Mutated (ATM) kinase.

Synthetic lethal drug combination for treating renal cell carcinoma

Pyridocarbazole-type compounds of formula (I): are provided as a medicament, and more particularly for application in anticancer chemotherapy. Also provided is a pharmaceutical composition with the compound and methods for preventing and/or treating neurodegenerative-type pathologies, such as Alzheimer's disease and schizophrenia, parasitoses, such as malaria, or glaucomas.

Pyridocarbazole type compounds and applications thereof

Growing community of inventors

Sassenage, France

Caroline Barette